Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313503237> ?p ?o ?g. }
- W4313503237 endingPage "6" @default.
- W4313503237 startingPage "6" @default.
- W4313503237 abstract "The benefits and safety of antidyslipidemia pharmacotherapy in patients with chronic kidney disease were not well defined so the latest evidence was summarized by this work.This systematic review and Bayesian network meta-analysis (NMA) included searches of PubMed, Embase, and Cochrane Library from inception to 28 February 2022, for randomized controlled trials of any antilipidaemic medications administered to adults with chronic kidney disease [CKD: defined as estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73 m2 not undergoing transplantation], using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool to assess the certainty of the evidence.55 trials and 30 works of them were included in our systematic review and NMA, respectively. In comparisons with no antidyslipidemia therapy or placebo, proprotein convertase subtilisin/Kexin type 9 inhibitors plus statin (PS) was the most effective drug regimen for reducing all-cause mortality (OR 0.62, 95% CI [0.40, 0.93]; GRADE: moderate), followed by moderate-high intensity statin (HS, OR 0.76, 95% CI [0.60, 0.93]; I2 = 66.9%; GRADE: moderate). PS, HS, low-moderate statin (LS), ezetimibe plus statin (ES), and fibrates (F) significantly decreased the composite cardiovascular events. The subgroup analysis revealed the null effect of statins on death (OR 0.92, 95% CI [0.81, 1.04]) and composite cardiovascular events (OR 0.94, 95% CI [0.82, 1.07]) in dialysis patients.In nondialysis CKD patients, statin-based therapies could significantly and safely reduce all-cause death and major composite cardiovascular events despite the presence of arteriosclerotic cardiovascular disease and LDL-c levels. Aggressive medication regimens, PS and HS, appeared to be more effective, especially in patients with established CAD." @default.
- W4313503237 created "2023-01-06" @default.
- W4313503237 creator A5018365310 @default.
- W4313503237 creator A5018497169 @default.
- W4313503237 creator A5033044240 @default.
- W4313503237 creator A5051590395 @default.
- W4313503237 creator A5062383247 @default.
- W4313503237 creator A5081090704 @default.
- W4313503237 creator A5083064056 @default.
- W4313503237 creator A5088503073 @default.
- W4313503237 date "2022-12-20" @default.
- W4313503237 modified "2023-09-26" @default.
- W4313503237 title "Antidyslipidemia Pharmacotherapy in Chronic Kidney Disease: A Systematic Review and Bayesian Network Meta-Analysis" @default.
- W4313503237 cites W140507299 @default.
- W4313503237 cites W1483531931 @default.
- W4313503237 cites W1502524639 @default.
- W4313503237 cites W1570859902 @default.
- W4313503237 cites W1617328014 @default.
- W4313503237 cites W1706399446 @default.
- W4313503237 cites W1755389849 @default.
- W4313503237 cites W1967917591 @default.
- W4313503237 cites W1978239396 @default.
- W4313503237 cites W1979397038 @default.
- W4313503237 cites W1979458837 @default.
- W4313503237 cites W1982966161 @default.
- W4313503237 cites W1992846720 @default.
- W4313503237 cites W1993251788 @default.
- W4313503237 cites W1993266652 @default.
- W4313503237 cites W1998295307 @default.
- W4313503237 cites W1998747783 @default.
- W4313503237 cites W1999573801 @default.
- W4313503237 cites W2008416254 @default.
- W4313503237 cites W2029977823 @default.
- W4313503237 cites W2044493153 @default.
- W4313503237 cites W2046358713 @default.
- W4313503237 cites W2060177619 @default.
- W4313503237 cites W2062364550 @default.
- W4313503237 cites W2067361204 @default.
- W4313503237 cites W2076748326 @default.
- W4313503237 cites W2076791931 @default.
- W4313503237 cites W2078421357 @default.
- W4313503237 cites W2082906144 @default.
- W4313503237 cites W2084325514 @default.
- W4313503237 cites W2093197048 @default.
- W4313503237 cites W2093676279 @default.
- W4313503237 cites W2097854176 @default.
- W4313503237 cites W2099618318 @default.
- W4313503237 cites W2105786988 @default.
- W4313503237 cites W2110601215 @default.
- W4313503237 cites W2116123427 @default.
- W4313503237 cites W2117848894 @default.
- W4313503237 cites W2122295878 @default.
- W4313503237 cites W2124905379 @default.
- W4313503237 cites W2126372860 @default.
- W4313503237 cites W2129575029 @default.
- W4313503237 cites W2134120087 @default.
- W4313503237 cites W2136245927 @default.
- W4313503237 cites W2137858397 @default.
- W4313503237 cites W2137865002 @default.
- W4313503237 cites W2139686302 @default.
- W4313503237 cites W2145493599 @default.
- W4313503237 cites W2155798268 @default.
- W4313503237 cites W2162430779 @default.
- W4313503237 cites W2164324917 @default.
- W4313503237 cites W2169205464 @default.
- W4313503237 cites W2186225706 @default.
- W4313503237 cites W2464867206 @default.
- W4313503237 cites W2470481127 @default.
- W4313503237 cites W2475261460 @default.
- W4313503237 cites W2512895854 @default.
- W4313503237 cites W2582602949 @default.
- W4313503237 cites W2604704258 @default.
- W4313503237 cites W2606701238 @default.
- W4313503237 cites W2616253374 @default.
- W4313503237 cites W2766211624 @default.
- W4313503237 cites W2771919228 @default.
- W4313503237 cites W2792772811 @default.
- W4313503237 cites W2892632954 @default.
- W4313503237 cites W2900034165 @default.
- W4313503237 cites W2904356389 @default.
- W4313503237 cites W2915967003 @default.
- W4313503237 cites W2941255624 @default.
- W4313503237 cites W2949589992 @default.
- W4313503237 cites W2953092106 @default.
- W4313503237 cites W2953804067 @default.
- W4313503237 cites W2970684805 @default.
- W4313503237 cites W3015163167 @default.
- W4313503237 cites W3080356411 @default.
- W4313503237 cites W3157248514 @default.
- W4313503237 cites W3183857127 @default.
- W4313503237 cites W3208790730 @default.
- W4313503237 cites W4211152466 @default.
- W4313503237 cites W4231467532 @default.
- W4313503237 cites W4249771864 @default.
- W4313503237 cites W4288535711 @default.
- W4313503237 doi "https://doi.org/10.3390/pharmaceutics15010006" @default.
- W4313503237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36678635" @default.
- W4313503237 hasPublicationYear "2022" @default.